CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?

Diffuse Large B-Cell Lymphoma

(2021) Laurie H. Sehn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

(2021) Paolo F Caimi et al.   LANCET ONCOLOGY

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

(2021) Gloria Iacoboni et al.   Cancer Medicine

WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMING

(2021) L. K Hilton et al.   HEMATOLOGICAL ONCOLOGY

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

(2021) Stephen J Schuster et al.   LANCET ONCOLOGY

Treatment resistance in diffuse large B-cell lymphoma

(2021) Michael Y. He et al.   LEUKEMIA

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

(2021) Sattva S. Neelapu et al.   BLOOD

Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology

(2021) Henry S. Ngu et al.   BLOOD

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

(2021) Jeremy S. Abramson et al.   BLOOD

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

(2021) Jeremy S. Abramson et al.   BLOOD

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

(2021) Caron Jacobson et al.   BLOOD

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

(2021) Manali Kamdar et al.   BLOOD

Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

(2021) Daniel J Landsburg et al.   BLOOD

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

(2021) Mahmoud Elsawy et al.   BLOOD

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

(2021) Frederick L. Locke et al.   BLOOD

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

(2021) Michael R. Bishop et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

(2021) Frederick L. Locke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

(2020) Michael D. Jain et al.   BLOOD

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

(2020) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.

(2020) Alison R. Sehgal et al.   JOURNAL OF CLINICAL ONCOLOGY

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

(2020) Caron A. Jacobson et al.   JOURNAL OF CLINICAL ONCOLOGY

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

(2020) Gilles Salles et al.   LANCET ONCOLOGY

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

(2020) Nagesh Kalakonda et al.   Lancet Haematology

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

(2020) Chelsea C. Pinnix et al.   Blood Advances

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

(2020) Kitsada Wudhikarn et al.   Blood Advances

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

(2019) Yucai Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2019) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

(2018) John Heymach et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

(2017) Gustaaf W. van Imhoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

(2014) Matthew J. Maurer et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

(2014) Michael Crump et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY